Related references
Note: Only part of the references are listed.The Distribution of mRNA Expression and Protein after Hydrodynamic Injection of Transgene in Mice
Yoshiyuki Hattori et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
NaCl Induced High Cationic Hydroxyethylated Cholesterol-Based Nanoparticle-Mediated Synthetic Small Interfering RNA Transfer into Prostate Carcinoma PC-3 Cells
Yoshiyuki Hattori et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts
Takashi Yoshizawa et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2008)
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma
J. W. B. de Groot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Technology Insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma
Marinella Messina et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Prospects of RNA interference therapy for cancer
SI Pai et al.
GENE THERAPY (2006)
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer
CJ Strock et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
The RET proto-oncogene:: A molecular therapeutic target in thyroid cancer
Y Kodama et al.
CANCER SCIENCE (2005)
Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines
K Kaczirek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (Iressa) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells
F Koizumi et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma
M Drosten et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Minireview: RET: Normal and abnormal functions
M Santoro et al.
ENDOCRINOLOGY (2004)
Antitumor capacity of a dominant-negative RET Proto-oncogene mutant in a medullary thyroid carcinoma model
M Drosten et al.
HUMAN GENE THERAPY (2003)
Surgical treatment of medullary thyroid carcinoma
MS Cohen et al.
JOURNAL OF INTERNAL MEDICINE (2003)
Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma
DJ Marsh et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
A new, therapeutic approach in medullary thyroid cancer treatment:: Inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant
M Drosten et al.
SURGERY (2002)
RET/PTC1 oncogene signaling in PCCl 3 thyroid cells requires the small GTP-binding protein Rho
MV Barone et al.
ONCOGENE (2001)
Multiple endocrine neoplasia type 2 and RET:: from neoplasia to neurogenesis
JR Hansford et al.
JOURNAL OF MEDICAL GENETICS (2000)
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway
C Segouffin-Cariou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions
R Hinze et al.
VIRCHOWS ARCHIV (2000)
Share Paper
